Table 1.
List of FDA approved CAR T cell therapies
| Drug name | Targeted gene | Delivery Strategy | Targeted malignancy | Data source |
|---|---|---|---|---|
|
Kymriah (Tisagenlecleucel) |
CD19 | Lentiviral |
Refractory/relapsed B cell acute lymphoblastic leukemia B-cell nonHodgkin Lymphoma Relapsed/Refractory Diffuse Large B cell Lymphoma |
[21, 41, 65, 66] |
|
Yescarta (Axicabtagene ciloleucel) |
CD19 | Gamma-retroviral |
Relapsed/Refractory Large B cell Lymphoma including Diffuse Large B cell Lymphoma and follicular lymphoma Relapsed/Refractory Mantle Cell Lymphoma |
[67, 68] |
|
Tecartus (Brexucabtagene autoleucel) |
CD19 |
Relapsed/Refractory Mantle Cell Lymphoma (MCL) (adults) Relapsed/Refractory Acute Lymphocytic Leukemia |
[69–71] | |
|
Abecma (Idecabtagene vicleucel) |
B cell maturation antigen (BCMA) | Lentiviral vector | Refractory and relapsed multiple myeloma | [72, 73] |
|
Breyanzi (Lisocabtagene maraleucel) |
CD19 | Lentiviral vector | Refractory and relapsed large B cell lymphoma | [74, 75] |
|
Carvykti (ciltacabtagene autoleucel) |
B cell maturation antigen (BCMA) | Relapsed/Refractory Multiple Myeloma | [76, 77] |